Ann: Trading Halt, page-216

You could be right!

From our annual report:
1. Dr Charmaine Gittleson told us - "We have also substantially completed the nine-month animal toxicology study, which I spoke about on many occasions last year, and which had become, inadvertently, a prerequisite for us to engage with the critical US market. At the time of writing, the initial data from that study seem generally consistent with prior studies, and we plan at this stage to share them with the FDA, most likely in the first half of CY2025, together with initial data from the phase IIb clinical trial."

If she didn't think the result is good enough why would she say that few months before the initial read out?

2. We expect that FY2025 will be the year in which we truly begin to reap the rewards of these patient and painstaking efforts. As I have noted on many occasions, the data from the phase IIb clinical trial of ATL1102 in DMDhas the potential to be transformative for the company. In parallel, we have been actively engaging in discussions with potential partners for the drug.

3. Dr. James Garner said, "Shareholders often ask about our strategy for partnering. Quite simply, the key priority, in our view, is to find the right partner– one which can devote resources and proven capabilities to ensuring that ATL1102 fulfils its potential. The quality of the partner is more important than the timing of a transaction or even the headline economics. We want to work with companies that share our belief in the drug, our dedication to high-quality science, and our commitment to patients. We make no apologies for bringing high expectations to such discussions: the program deserves no less."


Dr. James Garner told us recently from Just stock:
We're working in the background on just really trying to get ATL1102 as ready for prime time as possible, we want to make sure that:

• whatever the outcome of the study,
• whatever interactions we have with regulatory agencies,
• whatever direction partnering discussions take us in,

We're ready to respond.

We have the drug as clean and as ready and as complete as it's possible to be,
there's a lot of work going behind the scenes
to get things shipshape
proud of the work the team's doing

It's coming together well.

Let's mark their words!!